Bryan F. Vaca-Cartagena
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bryan F. Vaca-Cartagena has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Alejandra Yu Lee-Mateus
Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic, Jacksonville, FL, USA
13 shared publications - David Abia-Trujillo
Division of Pulmonary, Allergy, and Sleep Medicine Mayo Clinic Jacksonville Florida USA
13 shared publications - Sebastian Fernandez-Bussy
Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic Florida, Jacksonville, FL, USA
12 shared publications - Alanna Barrios-Ruiz
Division of Pulmonary, Allergy and Sleep Medicine, Mayo Clinic, Jacksonville, Florida, USA, mayo.edu
11 shared publications - Sofia Valdes-Camacho
Division of Pulmonary, Allergy, and Sleep Medicine, Mayo Clinic Florida, Jacksonville, FL, USA
11 shared publications - Rodrigo Funes-Ferrada
Division of Pulmonary, Allergy, and Sleep Medicine Mayo Clinic Jacksonville Florida USA
10 shared publications
Latest Publications
- 9 February 2026
- Published by Elsevier in Patient Education and Counseling
- Vol. 147, 109536
Genetic cancer risk knowledge among Mexican pathogenic variant carriers
- 9 February 2026
- Published by Elsevier in Patient Education and Counseling
- Vol. 147, 109536
Genetic cancer risk knowledge among Mexican pathogenic variant carriers
- Open Access
- 1 January 2026
- Published by Wiley in Pulmonary Medicine
- Vol. 2026 (1) , e3558336
Feasibility and Safety of 1.1‐mm Cryobiopsy for Acute Rejection Surveillance in Lung Transplant Recipients: A Comparative Study and Review of the Literature
Background: Identifying graft rejection after lung transplantation remains challenging, and no consensus exists on the optimal surveillance strategy. Transbronchial forceps biopsy (FBx) is the conventional method but is limited by small sample size and crush artifacts. Sheath‐guided cryobiopsy (CBx) using a novel 1.1‐mm probe has emerged as a promising alternative. This study evaluates the feasibility and safety of the 1.1‐mm cryoprobe and provides a focused review of current literature. Methods: We conducted a retrospective observational single‐center study between October 2022 and January 2023 of adult lung transplant recipients who underwent transbronchial biopsies for surveillance. Procedures were performed using either standard FBx or the 1.1‐mm cryoprobe. Descriptive analyses compared feasibility and safety between groups. Results: We identified 72 lung transplant recipients who underwent 109 surveillance biopsies. A total of n = 56 CBx and n = 53 FBx procedures were performed. The median procedure time was 20 min (IQR 17–26) in the CBx group versus 22 min (IQR 15–33) in the FBx group. We found a statistically higher median sample area for CBx compared with FBx (11 vs. 6 mm 2 , p < 0.01). No pneumothorax or postprocedural respiratory failure occurred in either group. Conclusion: CBx with a 1.1‐mm probe provides larger histological samples than FBx, with comparable safety and potentially shorter procedural times. These findings support its feasibility for lung transplant surveillance.
- 1 January 2026
- Published by Wiley in Pulmonary Medicine
- Vol. 2026 (1) , e3558336
Open AccessFeasibility and Safety of 1.1‐mm Cryobiopsy for Acute Rejection Surveillance in Lung Transplant Recipients: A Comparative Study and Review of the Literature
Background: Identifying graft rejection after lung transplantation remains challenging, and no consensus exists on the optimal surveillance strategy. Transbronchial forceps biopsy (FBx) is the conventional method but is limited by small sample size and crush artifacts. Sheath‐guided cryobiopsy (CBx) using a novel 1.1‐mm probe has emerged as a promising alternative. This study evaluates the feasibility and safety of the 1.1‐mm cryoprobe and provides a focused review of current literature. Methods: We conducted a retrospective observational single‐center study between October 2022 and January 2023 of adult lung transplant recipients who underwent transbronchial biopsies for surveillance. Procedures were performed using either standard FBx or the 1.1‐mm cryoprobe. Descriptive analyses compared feasibility and safety between groups. Results: We identified 72 lung transplant recipients who underwent 109 surveillance biopsies. A total of n = 56 CBx and n = 53 FBx procedures were performed. The median procedure time was 20 min (IQR 17–26) in the CBx group versus 22 min (IQR 15–33) in the FBx group. We found a statistically higher median sample area for CBx compared with FBx (11 vs. 6 mm 2 , p < 0.01). No pneumothorax or postprocedural respiratory failure occurred in either group. Conclusion: CBx with a 1.1‐mm probe provides larger histological samples than FBx, with comparable safety and potentially shorter procedural times. These findings support its feasibility for lung transplant surveillance.
- Open Access
- 1 January 2026
- Published by Wiley in Case Reports in Infectious Diseases
- Vol. 2026 (1)
Nebulized Liposomal Amphotericin B as an Alternative Therapy for an Aspergillus Tracheal Plaque
Invasive pulmonary aspergillosis (IPA) typically affects immunocompromised individuals; however, increasing cases in patients without traditional risk factors suggest evolving host susceptibility and predisposing airway pathology. We present a case of an Aspergillus tracheal plaque in a 68‐year‐old immunocompetent woman with atypical presentation. Due to adverse effects associated with systemic antifungal therapy, treatment was transitioned to nebulized liposomal amphotericin B (LAmB), resulting in complete plaque resolution without complications. This case highlights the potential role of nebulized LAmB as an alternative treatment for tracheal aspergillosis. Further studies are warranted to refine dosing and expand its clinical applications.
- 1 January 2026
- Published by Wiley in Case Reports in Infectious Diseases
- Vol. 2026 (1)
Open AccessNebulized Liposomal Amphotericin B as an Alternative Therapy for an Aspergillus Tracheal Plaque
Invasive pulmonary aspergillosis (IPA) typically affects immunocompromised individuals; however, increasing cases in patients without traditional risk factors suggest evolving host susceptibility and predisposing airway pathology. We present a case of an Aspergillus tracheal plaque in a 68‐year‐old immunocompetent woman with atypical presentation. Due to adverse effects associated with systemic antifungal therapy, treatment was transitioned to nebulized liposomal amphotericin B (LAmB), resulting in complete plaque resolution without complications. This case highlights the potential role of nebulized LAmB as an alternative treatment for tracheal aspergillosis. Further studies are warranted to refine dosing and expand its clinical applications.
- Open Access
- 1 December 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (12) , 11144-11151
Feasibility and safety of argon plasma coagulation as hemostatic tool during medical thoracoscopy
Background: Medical thoracoscopy (MT) is a minimally invasive procedure used for diagnosing and managing undiagnosed pleural effusions. Argon plasma coagulation (APC) is a non-contact electrosurgical technique widely used in gastrointestinal and bronchoscopic procedures, yet its application in MT remains underreported. This study describes the APC technique during MT for hemostasis and evaluates its safety and feasibility. Methods: We conducted a retrospective observational study of patients who underwent MT with APC at Mayo Clinic, Jacksonville, FL, between December 1, 2022 and April 4, 2024. Patient demographics, procedural details, and pleural fluid analysis were recorded. Hemostasis was achieved using a rigid APC applicator, with bleeding severity assessed using the Validated Intraoperative Bleeding Scale (VIOPS). Descriptive statistical analyses were performed. Results: Twenty patients (median age: 72 years) underwent MT with APC, primarily for recurrent pleural effusion (95%). Adhesiolysis was performed in 60% of cases, and pleural biopsies were obtained in 95%. The median pleural fluid volume removed was 642.5 mL. A single bleeding complication (5%) was recorded (VIOPS score ≥2). No cases of air embolism were observed. Histopathology revealed malignancy in 21.1% of biopsies. Conclusions: MT with APC appears to be a safe and effective technique for achieving hemostasis following pleural biopsy, with a low complication rate. This study provides a foundation for future research on the role of APC in pleuroscopy and its potential advantages over conventional hemostatic techniques.
- 1 December 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (12) , 11144-11151
Open AccessFeasibility and safety of argon plasma coagulation as hemostatic tool during medical thoracoscopy
Background: Medical thoracoscopy (MT) is a minimally invasive procedure used for diagnosing and managing undiagnosed pleural effusions. Argon plasma coagulation (APC) is a non-contact electrosurgical technique widely used in gastrointestinal and bronchoscopic procedures, yet its application in MT remains underreported. This study describes the APC technique during MT for hemostasis and evaluates its safety and feasibility. Methods: We conducted a retrospective observational study of patients who underwent MT with APC at Mayo Clinic, Jacksonville, FL, between December 1, 2022 and April 4, 2024. Patient demographics, procedural details, and pleural fluid analysis were recorded. Hemostasis was achieved using a rigid APC applicator, with bleeding severity assessed using the Validated Intraoperative Bleeding Scale (VIOPS). Descriptive statistical analyses were performed. Results: Twenty patients (median age: 72 years) underwent MT with APC, primarily for recurrent pleural effusion (95%). Adhesiolysis was performed in 60% of cases, and pleural biopsies were obtained in 95%. The median pleural fluid volume removed was 642.5 mL. A single bleeding complication (5%) was recorded (VIOPS score ≥2). No cases of air embolism were observed. Histopathology revealed malignancy in 21.1% of biopsies. Conclusions: MT with APC appears to be a safe and effective technique for achieving hemostasis following pleural biopsy, with a low complication rate. This study provides a foundation for future research on the role of APC in pleuroscopy and its potential advantages over conventional hemostatic techniques.
- Open Access
- 1 October 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (10) , 7711-7723
Evaluating the effectiveness of staged versus simultaneous bilateral lung volume reduction surgery in patients with severe emphysema
Background: Lung volume reduction surgery (LVRS) is an effective treatment for patients with severe emphysema. Most studies favor a bilateral approach over unilateral LVRS. However, there is limited literature comparing the outcomes of sequential bilateral “staged” versus simultaneous bilateral LVRS. Here, we evaluated the safety and effectiveness of these two approaches. Methods: This retrospective cohort study included patients with severe emphysema who underwent LVRS at two tertiary referral centers. Pre- and postoperative-pulmonary function tests were used to assess outcomes. Descriptive statistics were used to explore associations between variables. For our survival analysis, we created a composite outcome combining overall survival and transplant-free survival, which was analyzed using Kaplan-Meier estimate and log-rank test. Cox proportional-hazard models identified factors associated with the composite outcome. Results: The study included 81 patients, the majority of whom were male (n=42, 52%) with a median age of 65 years [interquartile range (IQR), 61–69 years]. Most underwent bilateral LVRS (n=60, 74%) while 21 (26%) had a staged approach. Baseline characteristics were similar between groups, except for age, with the bilateral group being significantly younger (P=0.03). Hospital length of stay was comparable between the bilateral {10.9 days [standard deviation (SD): 8.13] and staged LVRS groups [13.5 days (SD: 13.2)]} (P=0.40). Rates of pneumonia (13% vs. 10%, P>0.99) and prolonged air leak (42% vs. 38%, P=0.77) were similar between the bilateral and staged groups, respectively. The only significant difference in surgical complication was subcutaneous emphysema, which occurred more frequently in the staged group (33% vs. 12%, P=0.04). At 5 years, the composite outcome was better in the staged approach {90.0% [95% confidence interval (CI): 73.2–100.0%] over bilateral LVRS [82.8% (95% CI: 73.0–93.9)]} (P=0.044). Univariable analysis revealed that longer hospital stays [hazard ratio (HR): 1.06, 95% CI: 1.01–1.10], need for transfusion during surgery (HR: 4.48, 95% CI: 1.16–17.35), and subcutaneous emphysema (HR: 3.72, 95% CI: 1.05–13.20) were predictors of a worse composite outcome. Regarding pulmonary function tests, the median time from pre- to post-surgical assessment was 6 months for the bilateral group and 22 months for the staged group. Both groups showed significant improvements in pulmonary function from baseline values. In the staged approach, the predicted forced expiratory volume in 1 second increased from 29.1% to 43.7% (PConclusions: Staged LVRS offered similar hospital length of stay and complication rates as bilateral LVRS. Both approaches led to clinically significant improvements in pulmonary function. Notably, the staged approach showed a better composite outcome of overall survival and transplant-free survival over simultaneous bilateral LVRS.
- 1 October 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (10) , 7711-7723
Open AccessEvaluating the effectiveness of staged versus simultaneous bilateral lung volume reduction surgery in patients with severe emphysema
Background: Lung volume reduction surgery (LVRS) is an effective treatment for patients with severe emphysema. Most studies favor a bilateral approach over unilateral LVRS. However, there is limited literature comparing the outcomes of sequential bilateral “staged” versus simultaneous bilateral LVRS. Here, we evaluated the safety and effectiveness of these two approaches. Methods: This retrospective cohort study included patients with severe emphysema who underwent LVRS at two tertiary referral centers. Pre- and postoperative-pulmonary function tests were used to assess outcomes. Descriptive statistics were used to explore associations between variables. For our survival analysis, we created a composite outcome combining overall survival and transplant-free survival, which was analyzed using Kaplan-Meier estimate and log-rank test. Cox proportional-hazard models identified factors associated with the composite outcome. Results: The study included 81 patients, the majority of whom were male (n=42, 52%) with a median age of 65 years [interquartile range (IQR), 61–69 years]. Most underwent bilateral LVRS (n=60, 74%) while 21 (26%) had a staged approach. Baseline characteristics were similar between groups, except for age, with the bilateral group being significantly younger (P=0.03). Hospital length of stay was comparable between the bilateral {10.9 days [standard deviation (SD): 8.13] and staged LVRS groups [13.5 days (SD: 13.2)]} (P=0.40). Rates of pneumonia (13% vs. 10%, P>0.99) and prolonged air leak (42% vs. 38%, P=0.77) were similar between the bilateral and staged groups, respectively. The only significant difference in surgical complication was subcutaneous emphysema, which occurred more frequently in the staged group (33% vs. 12%, P=0.04). At 5 years, the composite outcome was better in the staged approach {90.0% [95% confidence interval (CI): 73.2–100.0%] over bilateral LVRS [82.8% (95% CI: 73.0–93.9)]} (P=0.044). Univariable analysis revealed that longer hospital stays [hazard ratio (HR): 1.06, 95% CI: 1.01–1.10], need for transfusion during surgery (HR: 4.48, 95% CI: 1.16–17.35), and subcutaneous emphysema (HR: 3.72, 95% CI: 1.05–13.20) were predictors of a worse composite outcome. Regarding pulmonary function tests, the median time from pre- to post-surgical assessment was 6 months for the bilateral group and 22 months for the staged group. Both groups showed significant improvements in pulmonary function from baseline values. In the staged approach, the predicted forced expiratory volume in 1 second increased from 29.1% to 43.7% (PConclusions: Staged LVRS offered similar hospital length of stay and complication rates as bilateral LVRS. Both approaches led to clinically significant improvements in pulmonary function. Notably, the staged approach showed a better composite outcome of overall survival and transplant-free survival over simultaneous bilateral LVRS.
- Open Access
- 1 July 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (7) , 5361-5370
Narrative review of diagnostic yield of navigational bronchoscopy for pulmonary nodules—a call for standardization
Background and Objective: Lung cancer remains the leading cause of cancer-related mortality worldwide, with peripheral pulmonary lesions (PPLs) being increasingly identified through screening programs. Navigational bronchoscopy, including electromagnetic and robotic-assisted bronchoscopy, is pivotal for biopsying these lesions. However, inconsistent definitions of diagnostic yield (DY) across studies hinder accurate assessment of bronchoscopy performance. This narrative review aims to clarify current DY definitions and advocate for a standardized approach. Methods: A narrative review of articles from January 2019 to July 2024 was conducted using PubMed, focusing on DY and its calculation in bronchoscopic procedures. Key Content and Findings: This review highlights significant inconsistencies in DY definitions, with some studies including follow-up assessments and nonspecific benign (NSB) findings, while others only consider immediate specific benign (SB) and malignant results. These discrepancies result in wide-ranging reported DY values, from 26.7% to 97%. Additionally, the review underscores the importance of distinguishing between DY and diagnostic accuracy (DA), as they assess different aspects of procedural performance and should not be used interchangeably. Simulation studies also demonstrate that cancer prevalence and methodological differences in DY calculation substantially affect study outcomes. Standardizing DY as a measure based solely on immediate SB and malignant findings—without follow-up—would allow faster study times and for easier comparison across different studies. Reporting disease prevalence within the study population is highly relevant as higher prevalence may inflate reported DY values. Conclusions: A standardized, strict definition of DY is crucial for accurately evaluating the diagnostic capacity of bronchoscopy. DY should not be confused with DA, as they measure distinct elements of performance. Adopting a strict definition of DY will enhance the comparability of study results, promote evidence-based decision-making, and help reduce unnecessary procedures while improving the reliability of diagnostic assessments in clinical practice.
- 1 July 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (7) , 5361-5370
Open AccessNarrative review of diagnostic yield of navigational bronchoscopy for pulmonary nodules—a call for standardization
Background and Objective: Lung cancer remains the leading cause of cancer-related mortality worldwide, with peripheral pulmonary lesions (PPLs) being increasingly identified through screening programs. Navigational bronchoscopy, including electromagnetic and robotic-assisted bronchoscopy, is pivotal for biopsying these lesions. However, inconsistent definitions of diagnostic yield (DY) across studies hinder accurate assessment of bronchoscopy performance. This narrative review aims to clarify current DY definitions and advocate for a standardized approach. Methods: A narrative review of articles from January 2019 to July 2024 was conducted using PubMed, focusing on DY and its calculation in bronchoscopic procedures. Key Content and Findings: This review highlights significant inconsistencies in DY definitions, with some studies including follow-up assessments and nonspecific benign (NSB) findings, while others only consider immediate specific benign (SB) and malignant results. These discrepancies result in wide-ranging reported DY values, from 26.7% to 97%. Additionally, the review underscores the importance of distinguishing between DY and diagnostic accuracy (DA), as they assess different aspects of procedural performance and should not be used interchangeably. Simulation studies also demonstrate that cancer prevalence and methodological differences in DY calculation substantially affect study outcomes. Standardizing DY as a measure based solely on immediate SB and malignant findings—without follow-up—would allow faster study times and for easier comparison across different studies. Reporting disease prevalence within the study population is highly relevant as higher prevalence may inflate reported DY values. Conclusions: A standardized, strict definition of DY is crucial for accurately evaluating the diagnostic capacity of bronchoscopy. DY should not be confused with DA, as they measure distinct elements of performance. Adopting a strict definition of DY will enhance the comparability of study results, promote evidence-based decision-making, and help reduce unnecessary procedures while improving the reliability of diagnostic assessments in clinical practice.
- Open Access
- 25 June 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (6) , e70261
Successful Treatment of Recurrent Airway Stenosis With Paclitaxel‐Coated Balloons: A Case Report
Although current treatment strategies for nonmalignant airway stenosis may offer short‐term relief, their effectiveness is limited by high recurrence rates, often requiring additional procedures. While paclitaxel‐coated balloons (PCB) have demonstrated effectiveness in treating stenosis across various vascular and nonvascular conditions, their evidence in recurrent airway stenosis remains limited. Here, we present the case of a 35‐year‐old female with bronchial stenosis who underwent multiple bronchoscopic interventions, all of which were complicated by restenosis. Following the addition of a PCB to the therapeutic regimen, the patient achieved sustained airway patency.
- 25 June 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (6) , e70261
Open AccessSuccessful Treatment of Recurrent Airway Stenosis With Paclitaxel‐Coated Balloons: A Case Report
Although current treatment strategies for nonmalignant airway stenosis may offer short‐term relief, their effectiveness is limited by high recurrence rates, often requiring additional procedures. While paclitaxel‐coated balloons (PCB) have demonstrated effectiveness in treating stenosis across various vascular and nonvascular conditions, their evidence in recurrent airway stenosis remains limited. Here, we present the case of a 35‐year‐old female with bronchial stenosis who underwent multiple bronchoscopic interventions, all of which were complicated by restenosis. Following the addition of a PCB to the therapeutic regimen, the patient achieved sustained airway patency.
- Open Access
- 1 May 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (5) , 2901-2911
Evaluating long-term bronchoscopic outcomes of tracheobronchoplasty in patients with expiratory central airway collapse
Background: Expiratory central airway collapse (ECAC) is characterized by symptoms of respiratory mechanical outflow obstruction. Open and robotic tracheobronchoplasty (TBP) are the preferred surgical approaches for severe cases. However, more studies are needed to compare their long-term outcomes. Here we evaluated changes after TBP. Methods: This retrospective cohort included patients with ECAC who underwent TBP. We evaluated patients with dynamic bronchoscopy, pulmonary function, and six-minute walk tests (6MWT) before and after surgery. We used the ECAC severity score to assess airway collapse, with nine indicating severity. We used descriptive statistics to explore associations between variables and linear mixed models to assess changes over time and to examine associations between variables and outcomes. Results: The study included 61 patients, the majority of whom were female (69%), with a median age of 63 years. Most patients underwent open TBP (n=33, 54%). Baseline characteristics were similar between surgical approaches. Patients who underwent open TBP improved the ECAC severity score from baseline to 1 year after surgery, with scores decreasing from 10.79 to 0.83 for the open approach and from 10.69 to 0.73 for the robotic approach. The two surgical techniques had no significant differences in this outcome (P=0.89). Pulmonary function tests remained stable over time, while the 6MWT showed a mean improvement of 76 m from baseline to 2 years post-surgery, regardless of the approach used. Conclusions: Both open and robotic TBP are effective treatment options for patients with ECAC, as they stabilize the central airways and improve long-term functional outcomes.
- 1 May 2025
- Published by AME Publishing Company in Journal of Thoracic Disease
- Vol. 17 (5) , 2901-2911
Open AccessEvaluating long-term bronchoscopic outcomes of tracheobronchoplasty in patients with expiratory central airway collapse
Background: Expiratory central airway collapse (ECAC) is characterized by symptoms of respiratory mechanical outflow obstruction. Open and robotic tracheobronchoplasty (TBP) are the preferred surgical approaches for severe cases. However, more studies are needed to compare their long-term outcomes. Here we evaluated changes after TBP. Methods: This retrospective cohort included patients with ECAC who underwent TBP. We evaluated patients with dynamic bronchoscopy, pulmonary function, and six-minute walk tests (6MWT) before and after surgery. We used the ECAC severity score to assess airway collapse, with nine indicating severity. We used descriptive statistics to explore associations between variables and linear mixed models to assess changes over time and to examine associations between variables and outcomes. Results: The study included 61 patients, the majority of whom were female (69%), with a median age of 63 years. Most patients underwent open TBP (n=33, 54%). Baseline characteristics were similar between surgical approaches. Patients who underwent open TBP improved the ECAC severity score from baseline to 1 year after surgery, with scores decreasing from 10.79 to 0.83 for the open approach and from 10.69 to 0.73 for the robotic approach. The two surgical techniques had no significant differences in this outcome (P=0.89). Pulmonary function tests remained stable over time, while the 6MWT showed a mean improvement of 76 m from baseline to 2 years post-surgery, regardless of the approach used. Conclusions: Both open and robotic TBP are effective treatment options for patients with ECAC, as they stabilize the central airways and improve long-term functional outcomes.
- Open Access
- 3 April 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (4) , e70167
Using Endobronchial Valves to Manage Pneumomediastinum
Endobronchial valves have a variety of potential applications, from lung volume reduction in patients with severe emphysema to closing cavities in those with drug‐resistant tuberculosis. This report presents two cases in which endobronchial valves were effectively used to treat pneumomediastinum.
- 3 April 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (4) , e70167
Open AccessUsing Endobronchial Valves to Manage Pneumomediastinum
Endobronchial valves have a variety of potential applications, from lung volume reduction in patients with severe emphysema to closing cavities in those with drug‐resistant tuberculosis. This report presents two cases in which endobronchial valves were effectively used to treat pneumomediastinum.
- 29 March 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 241, 108061
Comparing the 1.1 mm cryoprobe versus flexible forceps for lung transplant acute allograft rejection diagnosis
- 29 March 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 241, 108061
Comparing the 1.1 mm cryoprobe versus flexible forceps for lung transplant acute allograft rejection diagnosis